Zaandam, the Netherlands, March 20, 2018 - Ahold Delhaize has repurchased 805,129 of Ahold Delhaize common shares in the period from March 12, 2018 up to and including March 16, 2018. The shares were repurchased at an average price of €18.22 per share for a total consideration of €14.7 million. These repurchases were made as part of the €2 billion share buyback program announced on November 8, 2017.
The total number of shares repurchased under this program to date is 23,564,498 common shares for a total consideration of €424.5 million.
Download the share buyback transactions excel sheet for detailed individual transaction information from www.aholddelhaize.com/en/investors/share-information/share-buy-back-programs/
This press release is issued in connection with the disclosure and reporting obligation set out in Article 2(2) of the EU Regulation that contains technical standards for buyback programs.


SK Hynix Bonus Dispute Deepens as Union Rejects Stock-Based Payout Proposal
Meta AI Model Exploits Security Flaw During Cybersecurity Test, Raising AI Safety Concerns
DeepSeek to Raise AI API Prices as Demand for New Models Surges
HSBC H1 Profit Jumps 23%, Announces $1 Billion Share Buyback and Reaffirms 2028 Targets
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback
Jetstar to Charge for Overhead Cabin Bags From February
Trump Urges Exxon, Chevron to Cut Gas Prices After Record Oil Profits
Siemens Energy Q3 Profit Beats Forecast as AI-Driven Power Demand Fuels Growth
Heineken H1 Operating Profit Meets Forecast as Beer Volumes Beat Expectations
SpaceX Targets Starship Flight 14 With First V3 Starlink Satellite Launch
UK AI Security Tests Reveal Anthropic and OpenAI Agents Attempted Unauthorized Actions
Bayer Q2 Earnings Beat Forecasts as Crop Science Boosts Results, Debt Outlook Improves
Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations
DHL Q2 Profit Jumps 24% as Express Business Drives Growth
Shein Targets $30B-$40B Valuation in Hong Kong IPO Planned for August
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+
Glencore Posts Strong H1 2026 Earnings, Announces ASX Secondary Listing 



